Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for AML Patients

NCT04826523 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04826523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04826523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for AML Patients
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
April 5, 2021
Completion date
October 20, 2025
Enrollment
150 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)